269 related articles for article (PubMed ID: 32964074)
1. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.
Farghaly H; Alshareef M; Alqarni A; Sayed M; Nasr H
Eur J Radiol Open; 2020; 7():100268. PubMed ID: 32964074
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of malignant thyroid lesions on [
Nasr H; Farghaly H; Alqarni A; Al-Salem S; Sayed M
Eur J Radiol Open; 2021; 8():100373. PubMed ID: 34458507
[TBL] [Abstract][Full Text] [Related]
3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
6. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
[TBL] [Abstract][Full Text] [Related]
7. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
11. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
12. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Dual Time Point
Einama T; Yamagishi Y; Takihata Y; Konno F; Kobayashi K; Yonamine N; Fujinuma I; Tsunenari T; Kouzu K; Nakazawa A; Iwasaki T; Shinto E; Ishida J; Ueno H; Kishi Y
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954351
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Role of Dual-Time-Point (18)F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma.
Lee S; Park T; Park S; Pahk K; Rhee S; Cho J; Jeong E; Kim S; Choe JG
Nucl Med Mol Imaging; 2014 Jun; 48(2):121-9. PubMed ID: 24900152
[TBL] [Abstract][Full Text] [Related]
16. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
17. Role of
Ma G; Zhang X; Wang M; Xu X; Xu B; Guan Z
Quant Imaging Med Surg; 2021 May; 11(5):2013-2018. PubMed ID: 33936982
[TBL] [Abstract][Full Text] [Related]
18. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]